EMAIL THIS PAGE TO A FRIEND

Orphanet journal of rare diseases

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.


PMID 25491744

Abstract

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited sensory and motor peripheral neuropathy. It is caused by PMP22 overexpression which leads to defects of peripheral myelination, loss of long axons, and progressive impairment then disability. There is no treatment available despite observations that monotherapeutic interventions slow progression in rodent models. We thus hypothesized that a polytherapeutic approach using several drugs, previously approved for other diseases, could be beneficial by simultaneously targeting PMP22 and pathways important for myelination and axonal integrity. A combination of drugs for CMT1A polytherapy was chosen from a group of authorised drugs for unrelated diseases using a systems biology approach, followed by pharmacological safety considerations. Testing and proof of synergism of these drugs were performed in a co-culture model of DRG neurons and Schwann cells derived from a Pmp22 transgenic rat model of CMT1A. Their ability to lower Pmp22 mRNA in Schwann cells relative to house-keeping genes or to a second myelin transcript (Mpz) was assessed in a clonal cell line expressing these genes. Finally in vivo efficacy of the combination was tested in two models: CMT1A transgenic rats, and mice that recover from a nerve crush injury, a model to assess neuroprotection and regeneration. Combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol, termed PXT3003, improved myelination in the Pmp22 transgenic co-culture cellular model, and moderately down-regulated Pmp22 mRNA expression in Schwannoma cells. In both in vitro systems, the combination of drugs was revealed to possess synergistic effects, which provided the rationale for in vivo clinical testing of rodent models. In Pmp22 transgenic CMT1A rats, PXT3003 down-regulated the Pmp22 to Mpz mRNA ratio, improved myelination of small fibres, increased nerve conduction and ameliorated the clinical phenotype. PXT3003 also improved axonal regeneration and remyelination in the murine nerve crush model. Based on these observations in preclinical models, a clinical trial of PTX3003 in CMT1A, a neglected orphan disease, is warranted. If the efficacy of PTX3003 is confirmed, rational polytherapy based on novel combinations of existing non-toxic drugs with pleiotropic effects may represent a promising approach for rapid drug development.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

71251
Acetic acid, analytical standard
C2H4O2
M3821 Anti-Myelin Basic Protein (MBP) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
90577
Bifido Selective Supplement B, for microbiology
C2H4O2
W302902
D-Sorbitol, ≥98%, FCC, FG
C6H14O6
240850
D-Sorbitol, 99%
C6H14O6
S1876
D-Sorbitol, ≥98%
C6H14O6
85529
D-Sorbitol, BioUltra, ≥99.5% (HPLC)
C6H14O6
S6021
D-Sorbitol, for molecular biology, ≥98%
C6H14O6
S7547
D-Sorbitol, BioXtra, ≥98%
C6H14O6
S3889
D-Sorbitol, BioReagent, cell culture tested, plant cell culture tested
C6H14O6
97336
D-Sorbitol, liquid, tested according to Ph.Eur.
C6H14O6
47841
D-Sorbitol, analytical standard
C6H14O6
1005706
Glacial acetic acid, United States Pharmacopeia (USP) Reference Standard
C2H4O2
N3136
Naltrexone hydrochloride
C20H23NO4 · HCl
Y0000400
Naltrexone hydrochloride, European Pharmacopoeia (EP) Reference Standard
C20H23NO4 · HCl
1617000
Sorbitol, United States Pharmacopeia (USP) Reference Standard
C6H14O6
S1000000
Sorbitol, European Pharmacopoeia (EP) Reference Standard
C6H14O6
PHR1006
Sorbitol, Pharmaceutical Secondary Standard; Certified Reference Material
C6H14O6
309532
Sorbitol F solution, 70 wt. % in H2O, Contains mainly D-sorbitol with lesser amounts of other hydrogenated oligosaccharides
C6H10O6
XNATG
SYBR® Green Extract-N-Amp Tissue PCR Kit, sufficient for 100 extractions, sufficient for 100 amplifications
XNATRG
SYBR® Green Extract-N-Amp Tissue PCR Kit, sufficient for 1000 extractions, sufficient for 1000 amplifications